The use of conformation-specific ligands and assays to dissect the molecular mechanisms of neurodegenerative diseases

Journal of Neuroscience Research

Volumn 85, Issue 11, 2007, Pages 2285-2297

  Leliveld, S Rutger ^a   Korth, Carsten ^b  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Conformation; Neurodegeneration; Oligomers; Protein

Indexed keywords

AMYLOID; CONGO RED; LIGAND; OLIGOMER; PRION PROTEIN; PROTEINASE; THIOFLAVINE;

ALZHEIMER DISEASE; ATOMIC FORCE MICROSCOPY; BETA SHEET; BIOCHEMISTRY; BIOPHYSICS; CONFORMATION; DEGENERATIVE DISEASE; IMMUNOASSAY; PRION DISEASE; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN STRUCTURE; REVIEW; ULTRACENTRIFUGATION;

AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; BRAIN CHEMISTRY; HUMANS; LIGANDS; NEURODEGENERATIVE DISEASES; PEPTIDES; PROTEIN CONFORMATION; PRPSC PROTEINS;

EID: 34547622291     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21353     Document Type: Review

References (131)

1. Alzheimer A. 1907. Ueber eine eigenartige Erkrankung der Himrinde. Cent Nervenheilk Psychiatr 30:177-179.
2. Arimon M, Diez-Perez I, Kogan MJ, Durany N, Giralt E, Sanz F, Fernandez-Busquets X. 2005. Fine structure study of Abeta1-42 fibrillogenesis with atomic force microscopy. FASEB J 19:1344-1346.
3. Baglioni S, Casamenti F, Bucciantini M, Luheshi LM, Taddei N, Chiti F, Dobson CM, Stefani M. 2006. Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci 26:8160-8167.
4. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T. 2003. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A 100:2023-2028.
5. Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H. 2005. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95:834-847.
6. Bennhold H. 1922. Eine specifische Amyloidfärbung mit Kongorot. Münchener Med Wochenschrift 44:1537.
7. Bessen RA, Marsh RF. 1992. Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent. J Virol 66:2096-2101.
8. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. 2003. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A 100:330-335.
9. Blake C, Serpell L. 1996. Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous beta-sheet helix. Structure 4:989-998.
10. Blennow K, de Leon MJ, Zetterberg H. 2006. Alzheimer's disease. Lancet 368:387-403.
11. Bohnen NI, Warner MA, Kokmen E, Beard CM, Kurland LT. 1994. Prior blood transfusions and Alzheimer's disease. Neurology 44:1159-1160.
12. Brown P, Gibbs CJ Jr, Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, Goldfarb LG, Gajdusek DC. 1994. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 35:513-529.
13. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M. 2002. Inherent toxic-ity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416:507-511.
14. Büeler H, Fisher M, Lang Y, Bluethmann H, Lipp H-P, DeArmond SJ, Prusiner SB, Aguet M, Weissmann C. 1992. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356:577-582.
15. Bukau B, Weissman J, Horwich A. 2006. Molecular chaperones and protein quality control. Cell 125:443-451.
16. Castilla J, Saa P, Hetz C, Soto C. 2005. In vitro generation of infectious scrapie prions. Cell 121:195-206.
17. Caughey B, Lansbury PT. 2003. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26:267-298.
18. Chien P, Weissman JS. 2001. Conformational diversity in a yeast prion dictates its seeding specificity. Nature 410:223-227.
19. Chiti F, Dobson CM. 2006. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75:333-366.
20. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. 2005. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8:79-84.
21. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A. 2006. Opposing activities protect against age onset proteotoxicity. Science (in press).
22. Dafforn TR, Smith CJ. 2004. Natively unfolded domains in endocytosis: hooks, lines and linkers. EMBO Rep 5:1046-1052.
23. Deshpande A, Mina E, Glabe C, Busciglio J. 2006. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci 26:6011-6018.
24. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. 1997. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993.
25. Divry P. 1927. Etude histochimique des plaques seniles. J Neurol Psychiatry 27:643.
26. Dyson HJ, Wright PE. 2005. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 6:197-208.
27. Fast J, Mossberg AK, Svanborg C, Linse S. 2005. Stability of HAMLET - a kinetically trapped alpha-lactalbumin oleic acid complex. Prot Sci 14:329-340.
28. Ferguson N, Becker J, Tidow H, Tremmel S, Sharpe TD, Krause G, Flinders J, Petrovich M, Berriman J, Oschkinat H, Fersht AR. 2006. General structural motifs of amyloid protofilaments. Proc Natl Acad Sci U S A 103:16248-16253.
29. Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Bakh WE, Kelly JW. 2006. Functional amyloid formation within mammalian tissue. PLoS Biol 4:e6.
30. Gibbs CJ Jr, Gajdusek DC, Asher DM, Alpers MP, Beck E, Daniel PM, Matthews WB. 1968. Creutzfeldt-Jakob disease (spongiform encephalopathy): transmission to the chimpanzee. Science 161:388-389.
31. Glenner GG, Wong CW. 1984. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885-890.
32. Glenner GG, Eanes ED, Page DL. 1972. The relation of the properties of Congo red-stained amyloid fibrils to the β-conformation. J Hhistochem Cytochem 20:821-826.
33. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. 1986. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261:6084-6089.
34. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, Mizushima N. 2006. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441:885-889.
35. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
36. Harper JD, Lansbury PT Jr. 1997. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66:385-407.
37. Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, Torchia M, DeArmond SJ, Prusiner SB, Lingappa VR. 1998. A transmembrane form of the prion protein in neurodegenerative disease. Science 279:827-834.
38. Hegde RS, Tremblay P, Groth D, DeArmond SJ, Prusiner SB, Lingappa VR. 1999. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 402:822-826.
39. Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey G, Moritz E, Nitsch RM. 2002. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med 8:1270-1275.
40. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Cervera P, Le Bouc Y. 2003. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421:182-187.
41. Hornemann S, Korth C, Oesch B, Riek R, Wide G, Wüthrich K, Glockshuber R. 1997. Recombinant full-length murine prion protein, mPrP(23-231): purification and spectroscopic characterization. FEBS Lett 413:277-281.
42. Hornemann S, Schorn C, Wuthrich K. 2004. NMR structure of the bovine prion protein isolated from healthy calf brains. EMBO Rep 5:1159-1164.
43. Hsiao K, Baker HF, Crow TJ, Poulter M, Owen F, Terwilliger JD, Westaway D, Ott J, Prusiner SB. 1989. Linkage of a prion protein missense variant to Gerstmann-Straussler syndrome. Nature 338:342-345.
44. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274:99-102.
45. Hsu AL, Murphy CT, Kenyon C. 2003. Regulation of aging and age-related disease by DAF-16 and heat-shock factor. Science 300:1142-1145.
46. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, Beyreuther K. 1996. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 271:22908-22914.
47. Jimenez JL, Nettleton EJ, Bouchard M, Robinson CV, Dobson CM, Saibil HR. 2002. The protofilament structure of insulin amyloid fibrils. Proc Natl Acad Sci U S A 99:9196-9201.
48. Sc conformational change. J Mol Biol 293:855-863.
49. Kascsak RJ, Rubenstein R, Merz PA, Tonna-DeMasi M, Fersko R, Carp RI, Wisniewski HM, Diringer H. 1987. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol 61:3688-3693.
50. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489.
51. Kirkitadze MD, Bitan G, Teplow DB. 2002. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies. J Neurosci Res 69:567-577.
52. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, Rowan MJ. 2005. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11:556-561.
53. Kohler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-497.
54. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, Tanaka K. 2006. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441:880-884.
55. Kong Q, Surewicz KA, Petersen RB, Zou W, Chen SG, Gambetti P, Parchi P, Capellari S, Goldfarb L, Montagna P, Lugaresi E, Piccardo P, Ghetti B. 2004. Inherited prion diseases. In: Prusiner SB, editor. Prion biology and diseases, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. p 673-775.
56. Korth C, Oesch B. 1996. Characterization of native and recombinant prion protein isoforms by differential exposure of antibody epitopes. Society for Neuroscience Meeting, Nov. 16-21, 1996, Washington, DC, S06-30.
57. Sc)-specific epitope defined by a monoclonal antibody. Nature 389:74-77.
58. Korth C, Streit P, Oesch B. 1999. Monoclonal antibodies specific for the native, disease-associated isoform of the prion protein. Methods Enzymol 309:102-112.
59. Korth C, Kaneko K, Groth D, Heye N, Telling G, Mastrianni J, Parchi P, Gambetti P, Will R, Ironside J, Heinrich C, Tremblay P, DeArmond SJ, Prusiner SB. 2003. Abbreviated incubation times for human prions in mice expressing a chimeric mouse-human prion protein transgene. Proc Natl Acad Sci U S A 100:4784-4789.
60. Kosik KS, Joachim CL, Selkoe DJ. 1986. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 83:4044-4048.
61. Sc by FACS using the prion specific antibody 15B3. International Neuroprion Conference, Oct 19-21, 2005, Düsseldorf, Germany, p 193.
62. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. 1998. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95:6448-6453.
63. Legname G, Baskakov IV, Nguyen HO, Riesner D, Cohen FE, DeArmond SJ, Prusiner SB. 2004. Synthetic mammalian prions. Science 305:673-676.
64. Legname G, Nguyen HO, Peretz D, Cohen FE, DeArmond SJ, Prusiner SB. 2006. Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc Natl Acad Sci U S A 103:19105-19110.
65. Leliveld SR, Dame RT, Wuite GJ, Stitz L, Korth C. 2006. The expanded octarepeat domain selectively binds prions and disrupts homomeric prion protein interactions. J Biol Chem 281:3268-3275.
66. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. 2006. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352-357.
67. Lingappa VR, Rutkowski DT, Hegde RS, Andersen OS. 2002. Conformational control through translocational regulation: a new view of secretory and membrane protein folding. Bioessays 24:741-748.
68. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, Schubert D, Riek R. 2005. 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci U S A 102:17342-17347.
69. Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J. 2006. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest 116:378-385.
70. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 82:4245-4249.
71. Mastrangelo IA, Ahmed M, Sato T, Liu W, Wang C, Hough P, Smith SO. 2006. High-resolution atomic force microscopy of soluble Abeta42 oligomers. J Mol Biol 358:106-119.
72. Mastrianni JA, Nixon R, Layzer R, Telling GC, Han D, DeArmond SJ, Prusiner SB. 1999. Prion protein conformation in a patient with sporadic fatal insomnia. N Engl J Med 340:1630-1638.
73. McKinley MP, Bolton DC, Prusiner SB. 1983. A protease-resistant protein is a structural component of the scrapie prion. Cell 35:57-62.
74. McLaurin J, Franklin T, Chakrabartty A, Fraser PE. 1998. Phosphatidyl-inositol and inositol involvement in Alzheimer amyloid-beta fibril growth and arrest. J Mol Biol 278:183-194.
75. McLaurin J, Golomb R, Jurewicz A, Antel JP, Fraser PE. 2000. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit Abeta-induced toxicity. J Biol Chem 275:18495-18502.
76. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SS, Mount HT, Fraser PE, Westaway D, St. George-Hyslop P. 2006. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12:801-808.
77. Mehlhorn I, Groth D, Stöckel J, Moffat B, Reilly D, Yansura D, Willett WS, Baldwin M, Fletterick R, Cohen FE, Vandlen R, Henner D, Prusiner SB. 1996. High-level expression and characterization of a purified 142-residue polypeptide of the prion protein. Biochemistry 35:5528-5537.
78. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M. 2006. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313:1781-1784.
79. Nelson R, Eisenberg D. 2006. Recent atomic models of amyloid fibril structure. Curr Opin Struct Biol 16:260-265.
80. Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R, Eisenberg D. 2005. Structure of the cross-beta spine of amyloid-like fibrils. Nature 435:773-778.
81. Novitskaya V, Makarava N, Bellon A, Bocharova OV, Bronstein IB, Williamson RA, Baskakov IV. 2006. Probing the conformation of the prion protein within a single amyloid fibril using a novel immunoconformational assay. J Biol Chem 281:15536-15545.
82. Oesch B, Jensen M, Nilsson P, Fogh J. 1994. Properties of the scrapie prion protein: quantitative analysis of protease resistance. Biochemistry 33:5926-5931.
83. O'Meara ES, Kukull WA, Schellenberg GD, Bowen JD, McCormick WC, Teri L, Pfanschmidt M, Thompson JD, Larson EB. 1997. Alzheimer's disease and history of blood transfusion by apolipoprotein-E genotype. Neuroepidemiology 16:86-93.
84. O'Nuallain B, Wetzel R. 2002. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci U S A 99:1485-1490.
85. Pan K-M, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, Mehlhorn I, Huang Z, Fletterick RJ, Cohen FE, Prusiner SB. 1993. Conversion of a-helices into b-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A 90:10962-10966.
86. Paramithiotis E, Pinard M, Lawton T, LaBoissiere S, Leathers VL, Zou WQ, Estey LA, Lamontagne J, Lehto MT, Kondejewski LH, Francoeur GP, Papadopoulos M, Haghighat A, Spatz SJ, Head M, Will R, Ironside J, O'Rourke K, Tonelli Q, Ledebur HC, Chakrabartty A, Cashman NR. 2003. A prion protein epitope selective for the pathologically misfolded conformation. Nat Med 9:893-899.
87. Peretz D, Scott M, Groth D, Williamson A, Burton D, Cohen FE, Prusiner SB. 2001. Strain-specified relative conformational stability of the scrapie prion protein. Prot Sci 10:854-863.
88. Peretz D, Williamson RA, Legname G, Matsunaga Y, Vergara J, Burton DR, DeArmond SJ, Prusiner SB, Scott MR. 2002. A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron 34:921-932.
89. Proctor CJ, Soti C, Boys RJ, Gillespie CS, Shanley DP, Wilkinson DJ, Kirkwood TB. 2005. Modelling the actions of chaperones and their role in ageing. Mech Ageing Dev 126:119-131.
90. Prusiner SB. 1982. Novel proteinaceous infectious particles cause scrapie. Science 216:136-144.
91. Prusiner SB. 2001. Shattuck Lecture - neurodegenerative diseases and prions. N Engl J Med 344:1516-1526.
92. Prusiner SB. 2004. Development of the prion concept. In: Prusiner SB, editor. Prion biology and diseases, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harrbor Laboratory Press. p 89-142.
93. Prusiner SB, McKinley MP, Bowman KA, Bolton DC, Bendheim PE, Groth DF, Glenner GG. 1983. Scrapie prions aggregate to form amyloid-like birefringent rods. Cell 35:349-358.
94. Prusiner SB, Groth D, Serban A, Koehler R, Foster D, Torchia M, Burton D, Yang S-L, DeArmond SJ. 1993. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci U S A 90:10608-10612.
95. Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, Wuthrich K. 1996. NMR structure of the mouse prion protein domain PrP(121-321). Nature 382:180-182.
96. Ritter C, Maddelein ML, Siemer AB, Luhrs T, Ernst M, Meier BH, Saupe SJ, Riek R. 2005. Correlation of structural elements and infectiviry of the HET-s prion. Nature 435:844-848.
97. Rowan MJ, Klyubin I, Wang Q, Anwyl R. 2005. Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies. Biochem Soc Trans 33:563-567.
98. Saa P, Castilla J, Soto C. 2005. Cyclic amplification of protein misfolding and aggregation. Methods Mol Biol 299:53-65.
99. Saborio GP, Permanne B, Soto C. 2001. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 411:810-813.
100. Sc molecules with different conformations. Nat Med 4:1157-1165.
101. Safar JG, Kellings K, Serban A, Groth D, Cleaver JE, Prusiner SB, Riesner D. 2005. Search for a prion-specific nucleic acid. J Virol 79:10796-10806.
102. Saghafi S, Spilman P, Tanz Z, Schreiber SS, Prusiner SB, DeArmond SJ, Lingappa VR. 2005. PrP topology as a determinant of pro- or anti-apoptotic functions. International Neuroprion Conference, Oct. 19-21, 2005, Düsseldorf, Germany. p51.
103. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
104. Selkoe DJ. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
105. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al. 1992. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359:325-327.
106. Si K, Lindquist S, Kandel ER. 2003. A neuronal isoform of the aplysia CPEB has prion-like properties. Cell 115:879-891.
107. 15N resonance assignment of parts of the HET-s prion protein in its amyloid form. J Biomol NMR 34:75-87.
108. +] factor by in vitro-converted Sup35 protein. Science 289:595-599.
109. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 1997. Alpha-synuclein in Lewy bodies. Nature 388:839-840.
110. Stahl N, Baldwin MA, Teplow DB, Hood L, Gibson BW, Burlingame AL, Prusiner SB. 1993. Structural analysis of the scrapie prion protein using mass spectrometry and amino acid sequencing. Biochemistry 32:1991-2002.
111. Stefani M, Dobson CM. 2003. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med 81:678-699.
112. Sticht H, Bayer P, Willbold D, Dames S, Hilbich C, Beyreuther K, Frank RW, Rosch P. 1995. Structure of amyloid A4-(1-40)-peptide of Alzheimer's disease. Eur J Biochem FEBS 233:293-298.
113. Sunde M, Serpell LC, Bartlam M, Fraser PE, Pepys MB, Blake CC. 1997. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 273:729-739.
114. Svensson M, Hakansson A, Mossberg AK, Linse S, Svanborg C. 2000. Conversion of alpha-lactalbumin to a protein inducing apoptosis. Proc Natl Acad Sci U S A 97:4221-4226.
115. Tanaka M, Chien P, Naber N, Cooke R, Weissman JS. 2004. Conformational variations in an infectious protein determine prion strain differences. Nature 428:323-328.
116. Tanaka M, Collins SR, Toyama BH, Weissman JS. 2006. The physical basis of how prion conformations determine strain phenotypes. Nature 442:585-589.
117. Taylor JP, Hardy J, Fischbeck KH. 2002. Toxic proteins in neurodegenerative disease. Science 296:1991-1995.
118. Telling GC, Parchi P, DeArmond SJ, Cortelli P, Montagna P, Gabizon R, Mastrianni J, Lugaresi E, Gambetti P, Prusiner SB. 1996. Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity. Science 274:2079-2082.
119. Tomaselli S, Esposito V, Vangone P, van Nuland NA, Bonvin AM, Guerrini R, Tancredi T, Temussi PA, Picone D. 2006. The alpha-to-beta conformational transition of Alzheimer's Abeta-(1-42) peptide in aqueous media is reversible: a step by step conformational analysis suggests the location of beta conformation seeding. Chem Biochem 7:257-267.
120. Tompa P. 2003. Intrinsically unstructured proteins evolve by repeat expansion. Bioessays 25:847-855.
121. Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, Walsh DM, Selkoe DJ. 2006. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 60:668-676.
122. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. 2002. Naturally secreted oligomers of amyloid beta protein potendy inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539.
123. Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, Betts V, Podlisny MB, Cleary JP, Ashe KH, Rowan MJ, Selkoe DJ. 2005. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans 33:1087-1090.
124. Weber P, Giese A, Piening N, Mitteregger G, Thomzig A, Beekes M, Kretzschmar HA. 2006. Cell-free formation of misfolded prion protein with authentic prion infectivity. Proc Natl Acad Sci U S A 103:15818-15823.
125. Westermark GT, Johnson KH, Westermark P. 1999. Staining methods for identification of amyloid in tissue. Methods Enzymol 309:3-25.
126. Wickner RB. 1994. [URE3] as an altered URE2 protein: evidence for a prion analog in Saccharomyces cerevisiae. Science 264:566-569.
127. +], and [Het-s]. In: Prusiner SB, editor. Prion biology and diseases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. p 305-372.
128. Wojcik C, Yano M, DeMartino GN. 2004. RNA interference of valosin-containing protein (VCP/p97) reveals multiple cellular roles linked to ubiquitin/proteasome-dependent proteolysis. J Cell Sci 117:281-292.
129. Wolozin BL, Pruchnicki A, Dickson DW, Davies P. 1986. A neuronal antigen in the brains of Alzheimer patients. Science 232:648-650.
130. Zhang Q, Powers ET, Nieva J, Huff ME, Dendle MA, Bieschke J, Glabe CG, Eschenmoser A, Wentworth P Jr, Lerner RA, Kelly JW. 2004. Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci U S A 101:4752-4757.
131. Zheng H, Koo EH. 2006. The amyloid precursor protein: beyond amyloid. Mol Neurodegen 1:5.